MAP/PATH, LLC

MAP/PATH

Disease Biomarkers Point Directly At Infection

The Enduring Global Health Crisis

Tuberculosis (TB) is not a disease of the past. Despite centuries of fighting this pathogen, it remains one of the world's most formidable health challenges.

Global Killer: TB is the leading infectious killer after the COVID-19 period, with over 10 million new cases reported globally each year.
The US Challenge: The CDC estimates that up to 13 million people in the United States have latent TB infection (LTBI).

Current testing relies on measuring the body's delayed immune response, leading to diagnostic gaps. MAP/PATH is solving this.

TB In The United States — A Dual Approach

The Bovine Connection —

Bovine Tuberculosis (bTB): Caused by Mycobacterium bovis, this is also an ancient disease affecting cattle and other warm-blooded animals, including humans.
Shared Heritage: Both human and bovine forms share an ancient heritage. The ongoing threat highlights the need for effective testing across species.

Public Health Focus —

While most Americans are at low risk, the CDC estimates that up to 13 million people in the United States have latent TB infection (LTBI).
Public Health Focus: The dual approach is critical: test for TB and treat TB disease and latent TB infection to prevent progression and reduce community transmission.
The Causative Agents: M. tuberculosis and Mycobacterium bovis (bTB) are the primary North American agents, both part of the Mycobacterium tuberculosis complex (MTBC).

Our Solution

Transforming TB Detection: Direct, Rapid, and Decentralized

Our rapid TB peptide test led to the national trademark PEPTAK™and its associated PEPTAK™ Kit. PEPTAK™is fundamentally different:

❌ Current Standard (TST/IGRA)

Indirect: Measures delayed immune system response.
Slow: Requires lab work, specialized training, and/or repeat visits.
Limited: Often detects after the immune system has responded.

✅ The PEPTAK™ Advantage

Direct: Uses a proprietary mAb to target TB-specific peptides circulating in the bloodstream.
Rapid: Provides qualitative LFA results in 15 minutes using just drops of blood on-site.
Early Detection: Allows for earlier detection of both latent and active disease states.

MAP/PATH, LLC

MAP/PATH

Introducing PEPTAK™: The Rapid, Point-of-Care TB Test Revolutionizing Early Detection

The Enduring Global Health Crisis

TB In The United States — A Dual Approach

Our Solution

Transforming TB Detection: Direct, Rapid, and Decentralized

Built On Patented Science

Contact Us

Send Message

MAP/PATH, LLC